职工医保基金支出近2万亿，全国医保最新“年报”透露哪些信息

Core Insights - The National Healthcare Security Administration (NHSA) released the "2024 National Medical Security Development Statistical Bulletin," highlighting key figures related to health insurance enrollment and fund operations [1][2]. Group 1: Health Insurance Enrollment and Fund Operations - As of the end of 2024, the total number of basic medical insurance participants reached 1.32662 billion, maintaining a coverage rate of 95% [2]. - The total revenue for the basic medical insurance fund (including maternity insurance) in 2024 was CNY 34,913.37 billion, while total expenditures reached CNY 29,764.03 billion, resulting in a cumulative fund balance of CNY 38,628.52 billion [2]. - The employee medical insurance fund (including maternity insurance) reported a revenue of CNY 23,732.47 billion in 2024, a 3.5% increase from the previous year, with expenditures of CNY 19,102.54 billion, marking a 7.6% increase [2]. Group 2: Medical Treatment and Benefits - In 2024, the number of treatment beneficiaries under employee medical insurance was 5.308 billion, reflecting a 9.9% increase year-on-year [3]. - The total medical expenses for employee medical insurance participants reached CNY 20,587.46 billion, which is a 3.6% increase compared to the previous year [3]. Group 3: Long-term Care and Cross-Region Medical Services - By 2024, 49 pilot cities had a total of 18,786.34 million participants in long-term care insurance, with the number of beneficiaries rising from 835,000 in 2020 to 1,462,500 in 2024 [5]. - The number of cross-region medical service visits reached 397 million in 2024, with associated costs amounting to CNY 7,867.74 billion [5]. Group 4: Drug Procurement and Insurance Directory Adjustments - The NHSA has conducted ten rounds of national drug procurement, covering 435 types of drugs, with the eleventh round focusing on established drugs with strict quality requirements [6][7]. - Since its establishment in 2018, the NHSA has dynamically adjusted the medical insurance drug directory for seven consecutive years, adding a total of 835 drugs, with 91 new drugs included in 2024 [8][9].